1 Pharmacokinetic parameters of trapidil (an antagonist of platelet derived growth factor) were evaluated in 12 healthy male subjects (study I) and in a group of 10 patients with liver cirrhosis (Child B) and five control subjects, respectively (study II). 2 Investigations were carried out after a single dose trapidil (200 mg) and at steady state after application of 200 mg trapidil three times daily for 5 days (study 1) or 4 days (study II ). 3 Study I: The concentration-time curves of the terminal elimination phase of trapidil exhibited a slight convexity which might reflect nonlinear kinetics. Table 2 . ated to desethyltrapidil which has similar, but about 10-fold weaker pharmacological properties with respect to platelet aggregation [ 11] . CYP450 isozymes involved in the degradation of trapidil have not yet been Investigations determined. This paper comprises the first studies reported on the single dose and steady state pharmacoStudy I. On day 1, plasma samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h after kinetics of trapidil in healthy subjects and in patients with impaired liver function.
Introduction
Subjects in study II were divided in two groups. Five patients without clinical or biochemical signs of liver damage were used as age-matched control group Trapidil, a triazolopyrimidine derivative, is currently used for treatment of chronic stable angina in several (group 1 ). All group 1 subjects had normal renal and hepatic function as assessed by physical examination European countries and in Japan. Trapidil has also been shown as effective as aspirin in preventing restenosis and appropriate biochemical tests. Two of the control subjects used oral contraceptives, two other control after percutaneous transluminal coronary angioplasty (PTCA) [1, 2] . Pharmacological effects of trapidil subjects received heparin. Group 2 comprised five patients suffering from ethanol-induced liver cirrhosis include vasodilatation mediated by phosphodiesterase (PDE)-inhibition [ 3] and reduction of platelet aggreand five patients with liver cirrhosis after previous infection with hepatitis B or C. Severity of liver disease gation due to thromboxane (TXA 2 )-inhibition [4 ] and antagonism of platelet derived growth factor of patients in group 2 was classified as Child B; eight patients had oesophageal varicosis. Active comedication (PDGF) [5 ] . In patients with coronary artery disease, arterial vasodilation and a decrease in diastolic filling was spironolactone in all patients, three patients received insulin. pressure has been observed after trapidil administration [ 6] resulting in antianginal activity [7] [8] [9] .
The following tests were carried out within a 2 week period before the study began to assess liver function Despite its long-term use in former East European countries and in Japan, little is known about the with regard to xenobiotic biotransformation: antipyrine (AP) clearance [12 ] , monoethylglycinxylidid-(MEGX ) pharmacokinetic properties of trapidil, and only data after single dose application have been reported [10 ] .
test [13] , indocyaninegreen (ICG) clearance [ 14] . Demographic data of patients and controls in study II Trapidil is completely absorbed and does not undergo first-pass metabolism [ 10] . Trapidil is primarily dealkyland the results of the quantitative tests for assessment of the liver function are given in Table 2 . ated to desethyltrapidil which has similar, but about 10-fold weaker pharmacological properties with respect to platelet aggregation [ 11] . CYP450 isozymes involved in the degradation of trapidil have not yet been Investigations determined. This paper comprises the first studies reported on the single dose and steady state pharmacoStudy I. On day 1, plasma samples were obtained before and 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h after kinetics of trapidil in healthy subjects and in patients with impaired liver function.
application of a single dose (capsule) containing 200 mg trapidil. From day 2 to day 4, trapidil was administered 200 mg three times daily. On day 5, after application of a last single dose (200 mg) of trapidil plasma samples were drawn as on day 1. On each of the pharmacokinetic Methods study days (i.e. days 1 and 5 ), trapidil intake followed an overnight fast, and a standardized breakfast was Study I was performed to investigate the pharmacokinetics of trapidil in 12 healthy male subjects after a served after 2 h. 200 mg single dose given on day 1 and day 5 following 200 mg three times daily trapidil during days 2 to 4. Study II. Investigations followed the same schedule as in study I, except there was a shorter treatment period Study II was carried out to assess the pharmacokinetics of trapidil in 10 patients with liver cirrhosis and five (3 instead of 4 days) and an additional blood sample was drawn 36 h after the last drug intake on day 4. age-matched subjects without liver disease after a 200 mg single dose given on day 1 and day 4 following 200 mg three times daily trapidil during days 2 and 3. The shorter treatment period in study II-carried out in T rapidil assay in-house patients -was due to logistic reasons.
Trapidil and desethyltrapidil (M1) were determined in plasma by an h.p.l.c.-method and u.v.-detection. Lower limit of quantification (LLQ) was 0.004 mg ml−1 for Subject selection and study protocol trapidil, linearity was proven up to 16 mg ml−1. For M1, LLQ was 0.001mg ml−1 and linearity was obtained Both studies were approved by the Institutional Review Board of the Frankfurt University Hospital, and study within 0.001 and 5 mg ml−1. Samples containing higher concentrations were re-analysed after dilution. Day-tosubjects gave their written informed consent.
Subjects in study I had a mean age of 29 years (range day variability was below 5%. 26-35 years), mean weight was 77 kg (range 65-98) and mean height was 178 cm (range 165-192 cm). All volunteers had normal renal and hepatic function as Pharmacokinetic evaluation assessed by physical examination and appropriate biochemical tests. They all were non-smokers and did All pharmacokinetic calculations were based on plasma concentrations which were above the LLQ. C max , t max not take any other medication for 2 weeks before and during the study. Electrocardiographic (12-lead) examinand C min (i.e. pre-dose plasma concentration at day 5[study I ] or day 4 [study II] were read directly ation revealed no signs of conduction abnormalities. from the plasma concentration-time curves of trapidil measured at 0.50 to 1.5 h after drug intake ( Figure 1a , Table 1 ). The AUC of trapidil obtained after the first and M1. The following pharmacokinetic parameters were obtained by using the non-compartmental analysis dose (20. Table 2 ). t max was reached earlier describes the area under the concentration-time curves at steady state (2-6 h vs 3-12 h). The AUC-ratio from time zero (pre-dose) over the time span of the (M1/trapidil ) increased from 0.68 to 1.28 at steady state dosing interval t (obtained with the logarithmic trap- (Table 1 ) , indicating an induction of this degradation ezoidal rule).
step [16 ] . However, AUC values of M1 obtained after The elimination half-life of trapidil was derived by the first dose and at steady state were not different suggesting that the apparent clearance of M1 is not
changed during steady state. The apparent clearance (assuming complete bioavailability of trapidil [10] ) of trapidil was determined by
The relative clearance of trapidil to M1 [ 16] was determined as ratio
Statistical analysis
Single dose vs steady state Primary target variables were the AUC, C max and t 1/2,z of trapidil and the AUC of desethyltrapidil. Confidence intervals of the ratio day 5 [or day 4, resp.]/day 1 were assessed after determination of the distribution of the logtransformed data.
Cirrhosis vs controls For study II, data of group 1 were compared with those of group 2 using the MannWhitney U-test. For the AUC of trapidil, non-parametric confidence intervals and the Hodges-Lehmann point estimator were obtained. The correlation between the quantitative liver function tests and the AUC of trapidil was assessed by linear regression analysis. In both studies, no differences were seen between the mg ml−1 h) in controls and (20.8 [±6.8 s.d.] mg ml−1 h) pre-and post-study laboratory tests. In study I, no in cirrhotic patients (Figure 2b , Table 3 ). The 90% adverse events were recorded. One patient in study II confidence intervals for the difference group 1 vs group 2 (group 2 ) experienced a transient episode of weakness was 0.88-2.20 (point estimator 1.45, U-test: P=0.05).
Results

Pharmacokinetic parameters
after the intake of the morning drug dose at days 2 However, the pattern of autoinduction seen in study I and 3 without further haemodynamic symptoms. was also present in study II in control subjects as well as Pharmacokinetic parameters of trapidil in this patient in cirrhotic patients. Plasma levels of desethyltrapidil at were not outstanding from the mean of his group. trough were higher in cirrhotic patients (3.80 [±3.15 s.d.] mg ml−1) when compared with control subjects (1.29 [±1.09 s.d.] mg ml−1) and subjects from study I ( Table 1) .
Active comedication of two patients with outstanding Discussion high AUC values (>2 s.d. of the mean of group 2) was explored, but no deviations from the medication patterns
The principal findings of the two studies reported here were that (1 ) trapidil metabolism exhibits autoinduction of the remaining subjects (comedication with spironolac- after repeated oral dosing, and (2 ) patients with liver cirrhosis exhibit a longer elimination half-life and compared with a 100 mg dose came up to 150% [data not published]. However, an explorative analysis of our reduced clearance of trapidil than healthy subjects.
Pharmacokinetic studies in patients with impaired data with non-linear models supplied within the TOPFIT software was not successful due to the only renal or hepatic function are formally required by drug approval authorities in order to exclude possible risks marginally visible convexity in the concentration-time curves and the lack of a validation procedure, e.g. by in these patient groups, e.g. due to cumulation. Since trapidil is metabolized extensively, an investigation in employing different dose levels per individual (for which similar V max and k d -values should be obtained). patients with liver cirrhosis was mandatory. In a further study trapidil kinetics were shown not to be affected by Trapidil metabolism is mainly due to N-dealkylation and hydroxylation [ 18, 19 ] . Data from study II indicate decreased renal function (glomerular filtration rate <30 ml−1 min) [ 17] .
that the clearance of trapidil is reduced in patients with liver cirrhosis by about 35%. The fact that we could The concentration-time curves of the terminal elimination phase of trapidil exhibited a slight convexity (see not detect a relationship between trapidil clearance and ICG clearance, the latter reflecting liver blood flow and inset of Figure 1a ) which might reflect non-linear kinetics. Non-linear kinetics have already been suggested hence the decrease in the intrinsic clearance of a drug [14] , is in accordance with the complete bioavailability from a single dose study with ascending oral doses, where the relative bioavailability of a 300 mg dose of trapidil without considerable first pass metabolism. The inverse correlation between the AUC of trapidil patients cannot be judged. Maximal plasma levels of trapidil are comparable between patients and controls, and the MEGX concentration suggests a decrease of phase-I-metabolism of trapidil, since MEGX is produced suggesting that any adverse effects due to extensive plasma peaks will not occur. Although trapidil elimination by CYP4503A4 dependent dealkylation and production rate is reduced not only with decreased liver blood flow half-life is increased, the relative short duration of t D,z and the autoinduction during steady state should prevent but also when the metabolic capacity is restricted [13 ] . However, no correlation was observed between trapidil cumulation even in cirrhotic patients. The results of our studies raise the question whether AUC and antipyrine-clearance, although antipyrine is also a low extraction drug metabolized by N-dealkythe short elimination half-life of trapidil, combined with the autoinduction of its metabolism, allows for sustained lation and hydroxylation [12] . Since the database of our study is small and CYP450 isozymes involved in plasma levels to maintain clinical efficacy. Unfortunately, we were not able to determine pharmacodynamic the degradation of trapidil have not yet been determined, we can only speculate that trapidil degradation pathways parameters during our studies. Clinical investigations in patients with coronary artery disease receiving chronic are not closely related to antipyrine metabolism (mainly CYP2C9 and CYP3A4 [ 20] ).
trapidil treatment showed that haemodynamic effects measured at the time of peak plasma levels were Induction of liver enzymes by trapidil has been suggested from early studies in rats and in rat liver comparable with those obtained after a single dose [ 7] , but no trough effects with regard to haemodynamics preparations, where trapidil as well as desethyltrapidil have been shown to decrease the hexobarbitone-induced and exercise duration could be detected. In addition to the presumably PDE-dependent vasodilating effects, sleeping time of rats [19, 21] and to induce the Ndemethylation of aminophenazone and the O-demethyltrapidil inhibits biosynthesis and action of TXA 2
[22] by 25% as well as PDGF activity [5] by 20% at in ation of codeine phosphate [19 ] . Autoinduction could not be confirmed by these in vitro experiments [21 ] .
vivo concentrations of about 10 mg ml−1. However, plasma levels of trapidil might not necessarily be However, both of our human studies showed clearly that the apparent oral clearance of trapidil is enhanced maintained throughout the dosing interval to obtain a therapeutic effect on platelet aggregation. In support of by about 20% after a treatment period of 3-4 days with 200 mg trapidil three times daily. It is suggested that this assumption the clinical efficacy of trapidil in prevention of restenosis after PTCA has been demonthe enhanced metabolism of trapidil during steady state is reflected by the earlier C max of M1 and the increase strated in two studies including 72 [1 ] and 256 [ 2] patients, respectively. Trapidil given 100 mg three times in the ratio AUC M1 /AUC trapidil [ 16] . In contrast, further degradation of M1 seems not to be affected by daily [2 ] and 200 mg three times daily [1 ] , respectively, was compared with aspirin 300 mg day−1 over 6 months, autoinduction, as the AUC values for M1 were not different when comparing single dose and steady state resulting in restenosis rates of 19% and 24 % under trapidil compared with 48% and 40% under aspirin. investigations.
The extent of the autoinduction in cirrhotic patients seems comparable with that observed in healthy subjects relevance of the decreased clearance of trapidil in cirrhotic
